Zacks Investment Research upgraded Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) to Hold in a report released today.
- Updated: March 20, 2017
Zacks Investment Research has upgraded Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) to Hold in a report released on 03/20/2017.
Yesterday Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) traded 14.03% higher at $8.78. The company’s 50-day moving average is $4.73 and its 200-day moving average is $3.34. The last stock close price is up 162.79% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. 27,755,289 shares of the stock were exchanged, up from an average trading volume of 6,519,340
See Chart Below
Aurinia Pharmaceuticals Inc has a 52 week low of $1.74 and a 52 week high of $10.54 The company’s market cap is currently $0.
In addition to Zacks Investment Research reporting its target price, a total of 5 firms have reported on the stock. The consensus target price is $8.05 with 3 firms rating the stock a strong buy, 2 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.
About Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)
Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.